{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:51:12Z","timestamp":1791881472706,"version":"4.3.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jaad.2025.08.005","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T06:35:59Z","timestamp":1754721359000},"page":"1448-1455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A phase 3, randomized, double-blind, active-controlled clinical study to compare BAT2206, a ustekinumab biosimilar, with ustekinumab reference product in patients with moderate-to-severe psoriasis: Treatment period 2 results (post Week 28 to Week 52)"],"prefix":"10.1016","volume":"93","author":[{"given":"Xiaoyong","family":"Man","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katya","family":"Zaharieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gra\u017cyna","family":"Pulka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"\u017bebrowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhua","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lally","family":"Mekokishvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cailing","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfeng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2025.08.005_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1021537","article-title":"Efficacy and safety profile of phosphodiesterase 4 inhibitor in the treatment of psoriasis: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Kang","year":"2022","journal-title":"Front Immunol"},{"issue":"16","key":"10.1016\/j.jaad.2025.08.005_bib2","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.3390\/jcm11164778","article-title":"Efficacy and safety of dimethyl fumarate in patients with moderate-to-severe plaque psoriasis: DIMESKIN-2, a multicentre single-arm Phase IIIB study","volume":"11","author":"Pellacani","year":"2022","journal-title":"J Clin Med"},{"issue":"16","key":"10.1016\/j.jaad.2025.08.005_bib3","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jaad.2025.08.005_bib4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial","volume":"184","author":"Warren","year":"2021","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.08.005_bib5","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/jdv.14114","article-title":"Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis","volume":"31","author":"Gisondi","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.jaad.2025.08.005_bib6","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.3390\/ijms18112427","article-title":"Treatment approaches to moderate to severe psoriasis","volume":"18","author":"Gisondi","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"10148","key":"10.1016\/j.jaad.2025.08.005_bib7","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"issue":"10201","key":"10.1016\/j.jaad.2025.08.005_bib8","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jaad.2025.08.005_bib9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2016.08.008","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.08.005_bib10","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/bjd.16426","article-title":"Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)","volume":"178","author":"Langley","year":"2018","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.08.005_bib11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s13555-024-01099-y","article-title":"The efficacy and safety of bimekizumab for plaque psoriasis: an expert consensus panel","volume":"14","author":"Burshtein","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaad.2025.08.005_bib12","article-title":"Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis-a randomized controlled trial (PSORRO)","volume":"30","author":"Gyldenl\u00f8ve","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"10","key":"10.1016\/j.jaad.2025.08.005_bib13","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jamadermatol.2021.3616","article-title":"Out-of-pocket costs of specialty medications for psoriasis and psoriatic arthritis treatment in the medicare population","volume":"157","author":"Pourali","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2025.08.005_bib14","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4161\/mabs.3.6.17815","article-title":"Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune mediated disorders","volume":"3","author":"Benson","year":"2011","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.jaad.2025.08.005_bib15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00063030-200923010-00006","article-title":"Ustekinumab","volume":"23","author":"Weber","year":"2009","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.jaad.2025.08.005_bib16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40259-022-00563-5","article-title":"Comparison of pharmacokinetic similarity, immunogenicity, and safety of ustekinumab and BAT2206 in healthy Chinese male subjects in a double-blind, randomized, single-dose, parallel-group Phase I trial","volume":"37","author":"Wu","year":"2023","journal-title":"BioDrugs"},{"issue":"4","key":"10.1016\/j.jaad.2025.08.005_bib17","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jaad.2024.10.104","article-title":"A randomized phase III study to Compare efficacy and safety of BAT2206 (proposed ustekinumab biosimilar) with reference ustekinumab in patients with moderate to severe plaque psoriasis","volume":"92","author":"Man","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"9625","key":"10.1016\/j.jaad.2025.08.005_bib18","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"issue":"9625","key":"10.1016\/j.jaad.2025.08.005_bib19","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jaad.2025.08.005_bib20","first-page":"379","article-title":"Design and analysis of biosimilar switching studies","volume":"33","author":"Chow","year":"2019","journal-title":"Pharmaceut Med"},{"issue":"1","key":"10.1016\/j.jaad.2025.08.005_bib23","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2436607","article-title":"Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52","volume":"35","author":"Feldman","year":"2024","journal-title":"J Dermatol Treat"},{"issue":"6","key":"10.1016\/j.jaad.2025.08.005_bib26","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40259-019-00377-y","article-title":"Evolution of the EU biosimilar framework: past and future","volume":"33","author":"Wolff-Holz","year":"2019","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.jaad.2025.08.005_bib27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40259-023-00630-5","article-title":"Efficacy and safety of candidate biosimilar CT-P43 versus originator ustekinumab in moderate to severe plaque psoriasis: 28-week results of a randomised, active-controlled, double-blind, phase III study","volume":"38","author":"Papp","year":"2024","journal-title":"BioDrugs"},{"issue":"5","key":"10.1016\/j.jaad.2025.08.005_bib28","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/13543784.2023.2215426","article-title":"A randomized, double-blind, 3-arm, parallel study assessing the pharmacokinetics, safety, tolerability and immunogenicity of AVT04, an ustekinumab candidate biosimilar, in healthy adults","volume":"32","author":"Wynne","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jaad.2025.08.005_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.675358","article-title":"A biosimilarity study between QX001S and ustekinumab in healthy Chinese male subjects","volume":"12","author":"Gao","year":"2021","journal-title":"Front Pharmacol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225025940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225025940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:24:54Z","timestamp":1791879894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225025940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0190962225025940"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.08.005","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 3, randomized, double-blind, active-controlled clinical study to compare BAT2206, a ustekinumab biosimilar, with ustekinumab reference product in patients with moderate-to-severe psoriasis: Treatment period 2 results (post Week 28 to Week 52)","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}